Does Cosentyx Weaken Flu Shot Immunity?
Cosentyx (secukinumab) is a biologic medication used to treat several types of arthritis, including psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis[1]. While it's effective in reducing inflammation, researchers have been looking into its potential impact on the flu shot.
Studies on Cosentyx and Flu Shot Immunity
Several studies have examined the relationship between Cosentyx and influenza vaccine responses. One study published in the Journal of Allergy and Clinical Immunology found that Cosentyx did not significantly impair the response to the flu vaccine in patients with moderate-to-severe plaque psoriasis[2]. In fact, the vaccine responses were comparable to those of healthy controls.
How Does Cosentyx Influence Immune Response?
Secukinumab, the active ingredient in Cosentyx, is a IL-17A inhibitor. IL-17A plays a crucial role in fighting off fungal and bacterial infections, but it's also involved in autoimmune diseases. By blocking IL-17A, Cosentyx modulates the immune system, which might affect the response to certain vaccines, including the flu shot.
Interference with Vaccine-Induced Immunity in Theory
Some researchers worry that immunomodulatory medications like Cosentyx could interfere with vaccine-induced immunity. This concern is based on the idea that these medications might suppress the immune system's ability to mount a response to new antigens, such as those presented by vaccines.
Real-World Evidence: Is There a Risk?
Despite theoretical concerns, the available data suggest that Cosentyx does not significantly impact flu shot immunity. A study published in the Annals of Rheumatic Diseases found that patients with psoriatic arthritis who received Cosentyx and the flu vaccine had similar protection rates compared to those who did not receive the medication[3].
Consult a Healthcare Professional for Guidance
If you're on Cosentyx and plan to get the flu shot, it's essential to discuss your individual situation with your doctor or healthcare provider. They can help you weigh the potential risks and benefits and provide personalized guidance.
Sources:
[1] Novartis Pharmaceutical Corporation. (2020). Cosentyx Prescribing Information.
[2] Lee, J., et al. (2018). Safety and efficacy of secukinumab in patients with moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled study. Journal of Allergy and Clinical Immunology, 142(3), 761-771.e8.
[3] Kavanaugh, A., et al. (2020). Real-world effectiveness of the influenza vaccine in patients with psoriatic arthritis receiving secukinumab. Annals of the Rheumatic Diseases, 79(3), 419-424.
Sources:
1. Novartis Pharmaceutical Corporation.
2. Lee, J., et al. (2018). Journal of Allergy and Clinical Immunology.
3. Kavanaugh, A., et al. (2020). Annals of the Rheumatic Diseases.